# Nebulising Liposomal Formulations

This is an advanced topic.

Most readers will not need it first.

The main question is whether liposomal formulations behave differently from free-drug aerosols in the lungs.

{% hint style="warning" %}
This page is educational only. It is not medical or treatment advice. Nebulising liposomal formulations raises separate formulation, sterility, particle-size, and pulmonary-safety questions that go beyond ordinary oral use.
{% endhint %}

### Main idea

Nebulised liposomal formulations can sometimes outperform non-liposomal versions in pulmonary delivery research.

The usual reasons are:

* higher lung deposition
* longer retention
* better intracellular uptake in lung tissue
* improved biofilm penetration
* more controlled release
* lower systemic exposure and toxicity in some models

The strongest support comes from inhaled drug-delivery research.

It does **not** mean every liposomal payload will behave this way.

Performance depends on the payload, lipid composition, particle size, nebuliser, and disease setting.

### Why liposomes may matter in the lungs

#### Increased lung deposition and retention

Some liposomal formulations remain in lung tissue longer than free-drug versions.

That can help sustain local exposure.

#### Improved uptake and targeting

Liposomes may be taken up efficiently by pulmonary macrophages and other lung cells.

That matters most when intracellular delivery is part of the goal.

#### Protection from degradation and controlled release

Liposomal encapsulation may protect compounds from faster degradation and clearance.

It may also slow-release after deposition.

#### Reduced systemic side effects

Localised delivery may reduce whole-body exposure compared with free-drug inhalation.

That benefit is formulation-specific.

#### Better biofilm penetration

This is one reason liposomal delivery has drawn interest in chronic lung infection settings.

Human relevance depends on the exact formulation and target organism.

### What the evidence does and does not say

The pulmonary-delivery literature lends the concept biological credibility.

It does not make improvised home nebulising safe.

Most published advantages come from purpose-built pharmaceutical or research formulations.

Those systems are designed around:

* defined particle size
* controlled lipid composition
* compatible excipients
* stability testing
* sterility standards
* device-specific performance

### Practical caution

That gap matters.

Home-made or improvised nebulised liposomal mixtures can behave very differently from formal inhalation products.

Nebulising adds new questions around:

* sterility
* droplet size
* excipient suitability
* airway irritation
* dose reproducibility
* device compatibility

Other practical issues include:

* pH and tonicity
* contamination risk after storage
* foaming or instability during nebulisation
* uncertain delivered dose per session

This is why the topic belongs in advanced reading, not a home protocol.

### Bottom line

Liposomal nebulisation is a serious formulation question, not a minor tweak.

In the right system, it may improve local delivery and retention.

That does **not** make DIY nebulising appropriate or low risk.

### Further reading on nebulising liposomes

<details>

<summary>Explore these articles related to nebulising liposomes</summary>

**Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications**\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC5588529/>[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/26938856/)

***

**Inhaled Liposomes – Current Strategies and Future Challenges for Pulmonary Drug Delivery**\
<https://err.ersjournals.com/content/30/161/210010>

***

**A Novel Approach for Lung Delivery of Drugs**\
<https://journals.lww.com/lungindia/fulltext/2015/32040/a_novel_approach_for_lung_delivery_of.5.aspx>

***

**Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design**\
<https://pubmed.ncbi.nlm.nih.gov/27848886/>[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/17540552/)

***

**Inhaled Liposomal Antimicrobial Delivery in Lung Infections**\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7479014/>

***

**Liposomal Drug Delivery Systems for Lung Diseases: Recent Advancement and Future Perspectives**\
\*(International Journal of Pharmaceutics, S0378517325007999)\*\
<https://www.sciencedirect.com/science/article/abs/pii/S0378517325007999>

***

**Advances and Challenges of Liposome Assisted Drug Delivery**\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4664963/>

***

**Nebulization and In Vitro Upper Airway Deposition of Liposomal Formulations**\
<https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c01146>[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC10988550/)

***

**Liposomes Are Poorly Absorbed via Lung Lymph After Inhaled Administration**\
<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.880448/full>[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC9201389/)

***

**Liposomes for Drug Delivery to the Lungs by Nebulization**\
\*(European Journal of Pharmaceutics and Biopharmaceutics, S0939641107001488)\*\
<https://www.sciencedirect.com/science/article/abs/pii/S0939641107001488>[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/17540552/)

***

**Liposomes for Inhalation**\
\*(Chapter in book, ScienceDirect B9780443223747000050)\*\
<https://www.sciencedirect.com/science/article/abs/pii/B9780443223747000050>

***

**Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases**\
<https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/anbr.202200106>[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/37266328/)

***

**Liposomal Drug Delivery Systems for Lung Diseases**\
\*(Journal of Drug Delivery Science and Technology, S1773224719318593)\*\
<https://www.sciencedirect.com/science/article/abs/pii/S1773224719318593>

***

**Liposomes as Inhalation Drug Delivery Systems for the Treatment of Pulmonary Diseases**\
\*(Drug Delivery, Taylor & Francis, 10.1080/10717544.2016.1177136)\*\
<https://www.tandfonline.com/doi/full/10.1080/10717544.2016.1177136>

***

**Liposomes for Drug Delivery to the Lungs**\
\*(European Journal of Pharmaceutics and Biopharmaceutics, S0939641122000157)\*\
<https://www.sciencedirect.com/science/article/abs/pii/S0939641122000157>

***

**Liposomes as Drug Delivery Systems in the Treatment of Cardiovascular Diseases**\
\*(Biomedicines, MDPI 2022, 10(9), 2179)\*\
<https://www.mdpi.com/2227-9059/10/9/2179>

***

**Liposomes for Inhalation**\
<https://www.liebertpub.com/doi/10.1089/jamp.2024.29112.hxo>[pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/38640446/)

***

**Liposomal Drug Delivery to the Lungs: A Post COVID-19 Scenario**\
<https://www.tandfonline.com/doi/abs/10.1080/08982104.2023.2199068>[tandfonline](https://www.tandfonline.com/doi/abs/10.1080/08982104.2023.2199068)

<br>

</details>

→ [Back to How to Use Empty Liposomes](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds.md)

→ [Previous: Liposomal Ivermectin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/liposomal-ivermectin.md)

### In this section

* [How to Use Empty Liposomes](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds.md)
* [Why Empty Liposomes Matter](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/why-empty-liposomes-matter.md)
* [Safety, Timing, and Stacking Cautions](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/safety-timing-and-stacking-cautions.md)
* [How to Use Liposence® Empty Liposomes](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/how-to-use-liposence-r-empty-liposomes.md)
* [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md)
* [Liposomal Ivermectin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/liposomal-ivermectin.md)

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/nebulising-liposomal-formulations.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.